Introduction
Background
Kuru is a fatal neurologic disease that is restricted to the highlands of New Guinea, where it has afflicted the Fore (pronounced for-ay) people, a tribe of remote highland natives. The word kuru means "trembling with fear" in their native language.
The disease is now almost nonexistent and is believed to have existed for only a short time before it was first described in 1957.1,2 (At that time, the older members of the tribe said that it had not existed during their youth, which would mean that it had existed for only 10-20 y.) The Fore were isolated both from Western civilization and from other natives by very mountainous terrain, and kuru has not been described in any other location.
Kuru was spread by the endocannibalistic funeral practices of the Fore. Family members were ritualistically cooked and eaten following their death, with the closest female relatives and children usually consuming the brain, which was the most infectious organ. The women scooped the brain tissue out with their bare hands and did not subsequently wash them for weeks. During this time, they were handling, caring for, and possibly infecting their young children.
The effects on the Fore were devastating, wiping out whole villages at the height of the disease. Kuru is caused by a prion and serves as a prototype for a group of prion diseases (scrapie in sheep, transmissible mink spongiform encephalopathy, bovine spongiform encephalopathy [BSE; also called mad cow disease]). It reached epidemic proportions by entering the Fore food chain. In humans, other prion diseases, including familial Creutzfeldt-Jakob disease (CJD), Gerstmann-Strãussler-Scheinker syndrome, and fatal familial insomnia, are transmitted by genetic mutations.
Kuru has largely disappeared today because cannibalism has been abolished among the Fore. The place of kuru in medicine is as a model for prion diseases such as BSE and the so-called variant Creutzfeldt-Jakob disease (vCJD), which is thought to be the consequence of the spreading of the BSE prion to humans.
One of the enduring mysteries of kuru is the origin. If it did not exist until the middle of the 20th century, where did it originate? A recent origin is likely, given the statements of the Fore and the fact that the disease's effects were so devastating that they could not have existed if the epidemic had been prolonged. Kuru differs clinically and pathologically from classic CJD, and it more closely resembles vCJD, which is associated with BSE and, therefore, scrapie.
BSE is spread from the consumption of infected beef. A similar spread of kuru from infected meat and, possibly, scrapie from imported sheep is possible.
Classic CJD is predominantly a dementing disease with relatively minor movement dysfunction, while kuru and vCJD are diseases that show profound disordered movement, tremors, and less dementia. In the case of kuru, there may be no dementia at all. Kuru may have been introduced into the Fore culture as a single (or a few) case(s) of a transmissible spongiform encephalopathy that crossed the species barrier and became widespread as a result of the endocannibalistic rituals practiced by the Fore.
No new cases of kuru have been reported for several decades; the disease may be extinct. Kuru has entered our culture at many levels—some medical as a prototype of prion disease and some cultural. A San Francisco–based rock group has chosen the name Kuru and received airplay of their music in April 2005. One of their pieces is titled "Brain Bleeding Cannibal Core," perhaps fitting for the disease for which they are named.
Pathophysiology
Prions are thought to be both the infectious agent and the cause of spongiform encephalopathy in animals and humans. The prion is a naturally occurring protein (termed prion protein [PrP]) found in the CNS and elsewhere.
In the alpha-helical configuration, PrP usually is sensitive to protease degradation and is termed PrP-sen. Disease results when the PrP is reconfigured into the beta-sheet configuration, which is resistant to protease degradation. This configuration is termed PrP-res. The PrP-res proteins are resistant not only to protease degradation but also to radiation, heat, and most other processes that destroy proteins. Neither the transmissible agent nor the disease-producing agent contains any DNA or RNA. Because they are naturally occurring proteins, immunologic response to the infection is absent.
The prion of kuru is infectious orally and is capable of transmission to nonhuman primates by this route and by direct introduction into various tissues. Scrapie may be transmitted to sheep from pastures that have previously been grazed by scrapie-infected sheep and have remained unused for as many as 30 years, demonstrating the extreme resistance of prions to degradation. CJD also has been transmitted iatrogenically by transplanted tissue such as dura mater grafts. Potential transmission via the blood supply has been suggested but never demonstrated.
Prions are capable of replicating themselves in organisms; or, more correctly, prions are capable of changing the existing PrP-sen to PrP-res. This change takes place particularly in the CNS. Resistance to degradation is the probable source of disease because prions accumulate within the CNS, causing amyloid collections and resulting in neurologic symptoms and the spongiform appearance on pathologic examination. Hence, the term spongiform encephalopathy is applied to this group of diseases.
The name prion has only recently gained wide acceptance, replacing previously used terms such as slow virus, infectious proteins, infectious amyloids, and crystal protein. Mice that lack the gene responsible for PrP cannot be infected with the agent causing spongiform encephalopathy. The lack of this protein has no apparent effect, except an alteration in the circadian rhythm of these mice. They have a normal life span. For this reason, the PrP has been proposed to be a redundant protein.
The PRNP gene has recently been identified as altering the susceptibility to prion infection. The gene has a polymorphism at site 129 for either methionine or valine and has been noted as showing a strong increase in susceptibility to kuru if methionine is present on both genes (M/M). All cases of vCJD in the United Kingdom have occurred in people of the M/M genotype as well.
The pathologic similarity between the spongiform encephalopathies and other degenerative brain diseases, such as Alzheimer disease, is the subject of speculation at this point.
Frequency
United States
This disease does not occur in the United States.
International
Kuru is restricted to the Fore, a people found in the New Guinea highlands; although one report exists of a case of a transmissible subacute spongiform encephalopathy in a visitor to the eastern highlands of New Guinea.3 Kuru was acquired during endocannibalistic funeral rituals that are no longer practiced; therefore, the disease is disappearing as well. During the late 1950s, when the disease was first described, it had an incidence of approximately 1 case per 100 residents. The incubation period may be as long as 3 decades. The Fore believe the disease began with the arrival of white men, and the idea that kuru may have began when individuals with CJD were introduced into the cannibalistic ritual has been proposed.
Mortality/Morbidity
The disease has no effective treatment and is uniformly fatal within 6 months to 2 years once the disease develops. The incubation period may be as short as 4 years or as long as 3 decades.
Race
Kuru has affected only the Fore of New Guinea.
Sex
Cases of kuru predominantly occurred in women and children because they were more likely to consume the brain during endocannibalistic feasts. As the disease began to disappear, the ratio of men to women became equal, reflecting the result of exposure in childhood, and children no longer developed the disease.
Age
The age of onset has steadily risen because only Fore who participated in the feasts are developing the disease, and the feasts have not been practiced since the 1970s.
Clinical
History
Kuru was present in only the Fore, a New Guinea highland tribe, but has now progressively disappeared following cessation of endocannibalism. Kuru has not been found outside this context; therefore, the possibility of any practitioner now encountering a case of kuru is extremely remote.- To establish the diagnosis of kuru, a member of the Fore tribe must have a clinical disease that is characteristic and should have a history of attending cannibalistic feasts.
- A history of the consumption of brain or nervous tissue was especially important.
- The amount of infected tissue eaten probably plays a role in development of the disease. The incubation period may be as long as 3 decades.
- The clinical presentation of Kuru is (was) remarkably uniform. The prodromal symptoms of headache and joint pains are followed 6-12 weeks later by difficulty in walking and then a cerebellar tremor, hence the name, which means "trembling in fear" in the language of the Fore. This tremor disappears during sleep and is worsened in situations of stress and anxiety.
- Patients soon require assistance with walking, either using a stick or accepting support from family members.
- The tremor then becomes course, making an upright position difficult for patients to maintain, and they become bedridden.
- Eventually, patients can no longer swallow or eat, and progressive wasting results.
- Death follows a clinical course of 3 months to 2 years, with most patients dying within a year of symptom onset.
- The disease may also be associated with progressive dementia, but this certainly is not always a prominent part of the illness, as is the case with classic CJD. Some authorities believe the dementia of kuru may have a metabolic origin.
- Patients with kuru have a tendency to laugh or cry without apparent reason.
- Memory usually is relatively spared until the disease becomes advanced, when patients may not recognize their families.
- This disease is so classic in its presentation that the Fore have been able to diagnose it with great accuracy themselves, even in the early forms. A report exists of a 4-year-old child who was able to diagnose himself: His mother had already died of kuru.
Physical
- Physical findings are initially limited to the CNS.
- The disease is characterized by ataxia and muscular weakness early in the course. At this point, unaided ambulation is still possible.
- The disease progresses to a stage in which patients must use a stick, crutch, or human assistance to walk.
- In the later stages, dysarthria and convergent strabismus develop.
- Eventually, patients can no longer stand without assistance and may even be unable to sit, raise their head, or roll over.
- Patients eventually lose the ability to chew, swallow, or control excretory processes. They then become progressively wasted.
- Death results from starvation, complicating pneumonia, or decubitus ulcers.
- Dementia is not a prominent part of the disease, and some authors, such as Zigas et al, feel that little or no dementia exists.
- As noted above, the lack of dementia is in contradistinction to classic CJD, which is characterized by predominant dementia and less so by ataxia and muscular findings (see History).
- Emotional lability is well described, with inappropriate laughing being one of the classic features.
- In a classic screening test, the affected patient was asked to stand on just one foot.
Causes
Kuru is a prion disease transmitted by endocannibalism. No evidence indicates spread in utero or via human milk.
More on Kuru |
Overview: Kuru |
| Differential Diagnoses & Workup: Kuru |
| Treatment & Medication: Kuru |
| Follow-up: Kuru |
| References |
| Next Page » |
References
Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. N Engl J Med. Nov 14 1957;257(20):974-8. [Medline].
Zigas V, Gajdusek DC. Kuru: clinical study of a new syndrome resembling paralysis agitans in natives of the Eastern Highlands of Australian New Guinea. Med J Aust. Nov 23 1957;44(21):745-54. [Medline].
Grabow JD, Campbell RJ, Okazaki H, et al. A transmissible subacute spongiform encephalopathy in a visitor to the eastern highlands of New Guinea. Brain. Dec 1976;99(4):637-58. [Medline].
Almond JW. Bovine spongiform encephalopathy and new variant Creutzfeldt-Jakob disease. Br Med Bull. 1998;54(3):749-59. [Medline].
Alpers MP. Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3707-13. [Medline].
Brandner S, Whitfield J, Boone K, Puwa A, O'Malley C, Linehan JM, et al. Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3755-63. [Medline].
Brown P, Bradley R. 1755 and all that: a historical primer of transmissible spongiform encephalopathy. BMJ. Dec 19-26 1998;317(7174):1688-92. [Medline].
Brown P, Will RG, Bradley R, et al. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis. Jan-Feb 2001;7(1):6-16. [Medline].
Carp RI, Kascsak RJ, Wisniewski HM, et al. The nature of the unconventional slow infection agents remains a puzzle. Alzheimer Dis Assoc Disord. Spring-Summer 1989;3(1-2):79-99. [Medline].
Chakraborty C, Nandi S, Jana S. Prion disease: a deadly disease for protein misfolding. Curr Pharm Biotechnol. Apr 2005;6(2):167-77. [Medline].
Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry. Jul 2005;76(7):906-19. [Medline].
Collinge J. Variant Creutzfeldt-Jakob disease. Lancet. Jul 24 1999;354(9175):317-23. [Medline].
Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF, et al. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3725-39. [Medline].
Fiorino AS. Sleep, genes and death: fatal familial insomnia. Brain Res Brain Res Rev. Oct 1996;22(3):258-64. [Medline].
Gajdusek DC. Kuru and Creutzfeldt-Jakob disease. Experimental models of noninflammatory degenerative slow virus disease of the central nervous system. Ann Clin Res. Oct 1973;5(5):254-61. [Medline].
Gajdusek DC. Kuru: an appraisal of five years of investigation. Eugen Q. Mar 1962;9:69-74. [Medline].
Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science. Sep 2 1977;197(4307):943-60. [Medline].
Gajdusek DC, Gibbs CJ Jr, Alpers M. Transmission and passage of experimental "kuru" to chimpanzees. Science. Jan 13 1967;155(759):212-4. [Medline].
Gajdusek DC, Reid LH. Studies on kuru. IV. The kuru pattern in Moke, a representative Fore village. Am J Trop Med Hyg. Jul 1961;10:628-38. [Medline].
Gajdusek DC, Zigas V. Studies on kuru. I. The ethnologic setting of kuru. Am J Trop Med Hyg. Jan 1961;10:80-91. [Medline].
Gajdusek DC, Zigas V, Baker J. Studies on kuru. III. Patterns of kuru incidence: demographic and geographic epidemiological analysis. Am J Trop Med Hyg. Jul 1961;10:599-627. [Medline].
Gardash'ian AM. [Kuru]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1969;69(5):767-72. [Medline].
Hadlow WJ. Scrapie and Kuru. Lancet. 1959;2:289-290.
Hornabrook RW. Kuru. Contemp Neurol Ser. 1975;12:71-90;294. [Medline].
Keohane C. The human prion diseases. A review with special emphasis on new variant CJD and comments on surveillance. Clin Exp Pathol. 1999;47(3-4):125-32. [Medline].
Lampert PW, Gajdusek DC, Gibbs CJ. Subacute spongiform virus encephalopathies. Scrapie, Kuru and Creutzfeldt-Jakob disease: a review. Am J Pathol. Sep 1972;68(3):626-52. [Medline].
Lee HS, Brown P, Cervenakova L, et al. Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. J Infect Dis. Jan 15 2001;183(2):192-196. [Medline].
Liberski PP, Brown P. Kuru: a half-opened window onto the landscape of neurodegenerative diseases. Folia Neuropathol. 2004;42 Suppl A:3-14. [Medline].
Liberski PP, Brown P. Kuru: its ramifications after fifty years. Exp Gerontol. Jan-Feb 2009;44(1-2):63-9. [Medline].
Lindenbaum S. Review. Understanding kuru: the contribution of anthropology and medicine. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3715-20. [Medline].
Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Beck J, et al. Genetic susceptibility, evolution and the kuru epidemic. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3741-6. [Medline].
Miller MW, Williams ES. Chronic wasting disease of cervids. Curr Top Microbiol Immunol. 2004;284:193-214. [Medline].
Mocsny N. The spongiform encephalopathies: prion diseases. J Neurosci Nurs. Oct 1998;30(5):302-6. [Medline].
Nagai M, Kubota R, Greten TF, et al. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis. Jan 15 2001;183(2):197-205. [Medline].
Nutr Rev. Nutrition and infection: cannibalism. Nutr Rev. Oct 1971;29(10):226-7. [Medline].
Owen F. The molecular biology of the transmissible dementias. Mol Cell Biol Hum Dis Ser. 1994;4:110-32. [Medline].
Polo JM. [The history and classification of human prion diseases]. Rev Neurol. Jul 16-31 2000;31(2):137-41. [Medline].
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. Apr 9 1982;216(4542):136-44. [Medline].
Ridley RM, Baker HF. The myth of maternal transmission of spongiform encephalopathy. BMJ. Oct 21 1995;311(7012):1071-5; discussion 1075-6. [Medline].
Serpell LC, Sunde M, Blake CC. The molecular basis of amyloidosis. Cell Mol Life Sci. Dec 1997;53(11-12):871-87. [Medline].
Simpson NE. The map of chromosome 20. J Med Genet. Dec 1988;25(12):794-804. [Medline].
Sy MS, Gambetti P, Wong BS. Human prion diseases. Med Clin North Am. May 2002;86(3):551-71, vi-vii. [Medline].
Toledano-Gasca A. Hypotheses concerning the aetiology of Alzheimer's disease. Pharmacopsychiatry. Aug 1988;21 Suppl 1:17-25. [Medline].
Tyler KL. Prions and prion diseases of the central nervous system. Curr Clin Top Infect Dis. 1999;19:226-51. [Medline].
Verdrager J. Kuru and "new variant" CJD. Southeast Asian J Trop Med Public Health. Sep 1997;28(3):535-40. [Medline].
Wadsworth JD, Joiner S, Linehan JM, Asante EA, Brandner S, Collinge J. Review. The origin of the prion agent of kuru: molecular and biological strain typing. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3747-53. [Medline].
Whitfield JT, Pako WH, Collinge J, Alpers MP. Mortuary rites of the South Fore and kuru. Philos Trans R Soc Lond B Biol Sci. Nov 27 2008;363(1510):3721-4. [Medline].
Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. Apr 6 1996;347(9006):921-5. [Medline].
Wojtowicz S. Multiple sclerosis and prions. Med Hypotheses. Jan 1993;40(1):48-54. [Medline].
Further Reading
Keywords
kuru, prion, prion-related disease, prion disease, human prion disease, spongiform encephalopathy, slow virus, infectious proteins, infectious amyloids, crystal protein, bovine spongiform encephalopathy, BSE, mad cow disease, scrapie, endocannibalism, Creutzfeldt-Jakob disease, CJD, variant Creutzfeldt-Jakob disease, vCJD, Gerstmann-Strãussler-Scheinker syndrome, fatal familial insomnia, Fore, New Guinea, prion protein, PrP, PRNP
Overview: Kuru